Zurück zu den Rankings

Reckitt Benckiser Group plc (RBGPF)

NEUTRAL
Consumer DefensiveHousehold & Personal ProductsUnited Kingdom

Fundamental

52

Kurs

$5150.00

Marktkapitalisierung

$32.48B

Teil 1 · Was das Unternehmen wert ist

Übersicht

Reckitt Benckiser makes and sells branded household health and hygiene products: disinfectants and cleaners such as Lysol and Dettol, over-the-counter medicines such as Nurofen and Strepsils, condoms under Durex, and infant formula through its Mead Johnson Nutrition unit. It manufactures its own products and sells them through supermarkets, pharmacies and e-commerce worldwide. On 31 December 2025 it completed the sale of its Essential Home division (Air Wick, Calgon, Cillit Bang and about 75 other brands) to Advent International, keeping a 30% stake in the buyer.

Wie das Geld verdient wird

Revenue comes from selling packaged consumer goods through retailers, who buy at wholesale prices and mark them up for shelf sale. Margins depend on brand strength: a well-known name lets Reckitt charge more than an unbranded or store-label equivalent for a nearly identical product. Since January 2025 the group reports by geography — Core Emerging Markets, Core Europe, Core North America — plus Mead Johnson Nutrition as a separate line, after moving away from its former Health/Hygiene/Nutrition split.

Wettbewerbsvorteil

Marke · Schmal

Reckitt owns a portfolio of category-leading brands built over decades — Dettol in disinfection, Durex in condoms, Nurofen in pain relief — that let it command a premium over unbranded rivals. The advantage is narrow rather than wide: retailers' own store brands and generic pharmacy equivalents compete directly on price in most of these categories, and brand loyalty alone does not stop customers from trading down when budgets tighten.

Was die Nachfrage antreibt

Defensiv

Most of the portfolio — disinfectants, pain relief, feminine care — covers routine household purchases that people keep buying even in a downturn, which cushions the group against recessions. The exception is infant nutrition, where demand tracks birth rates rather than the economy: Mead Johnson's growth in 2025 came mainly from price and mix rather than more babies being fed, since volumes actually declined.

Die Argumente dafür

Buyers argue that the 2025 turnaround is real — Core Reckitt like-for-like revenue grew 5.2%, led by double-digit growth in Emerging Markets — and that the Essential Home sale sharpens the portfolio around higher-margin health and hygiene brands while returning capital to shareholders through a special dividend.

Die Argumente dagegen

Sellers point to a stalled Europe (like-for-like revenue down 4.5% in 2025) and soft North America, and worry that hundreds of pending U.S. lawsuits alleging Enfamil premature-infant formula causes necrotizing enterocolitis — with a jury already awarding $60 million in one case — could impose costs and reputational damage far beyond what today's price assumes.

Written by the editors, published on 18. August 2026

Direct competitors

Who this company fights with for the same customers

No editorial profile for this company yet

No competitor list for this company yet.

Bilanz & Liquidität

Umsatz

$13.35B

Letzte 12 Monate bis zum zuletzt gemeldeten Quartal — Schätzung aus Kennzahlen je Aktie

Nettogewinn

$2.81B

Letzte 12 Monate bis zum zuletzt gemeldeten Quartal — Schätzung aus Kennzahlen je Aktie

Freier Cashflow

$3.09B

Gesamtes Eigenkapital

$5.67B

Gesamtverbindlichkeiten

$10.25B

Current Ratio

0.59

Zinsdeckungsgrad

-

Schulden/EBITDA

2.86

Gewinn je Aktie

Umsatz & Nettogewinn

Freier Cashflow

Ertragsaufschlüsselung

Historische Aufstellung

Margen im Zeitverlauf

Verschuldung im Zeitverlauf

Wie schwer die Schulden wiegen

Wachstumsraster

Wachstum — Umsatz

Innerer-Wert-Schätzung

Überbewertet

Innerer Wert

$2156.36

Aktueller Kurs

$5150.00

Sicherheitsmarge

-138.8%

Innerer-Wert-Spanne

$1401.63 - $2911.08

Bewertungsmethoden

Analyst Target:$6223.26
DCF:$178.69
PE-based:$61.40
Graham Growth:$220.37
EPV:$42.58
Analystenkonsens:Starker Kauf (22B / 7H / 0S)
Letzte Gewinnüberraschung:-1.27%

Bewertungskennzahlen

P/E-Verhältnis

1169.99

ROE

48.0%

P/B-Verhältnis

580.17

P/FCF

1049.76

Bruttomarge

59.6%

ROIC

12.3%

Rentabilitäts-Radar

Value Creation (Economic Moat)

ROIC

12.3%

WACC

8.5%

ROIC − WACC

+3.8 pp

ROIC exceeds the cost of capital — the company is creating value for shareholders.

Fundamentalanalyse-Kriterien

Bestanden (10)

  • ROIC 12.3%
  • Gross Margin 59.6%
  • Debt/Equity ratio
  • Operating Margin 28.5%
  • Positive Free Cash Flow
  • Debt/EBITDA
  • ROE 42.9%
  • Analyst Consensus 76% Buy
  • PEG Ratio 0.47
  • Net Margin Trend 22.4% vs 10.1%

Nicht bestanden (11)

  • Price CAGR -3.27%
  • P/FCF 1049.76
  • P/B Ratio 580.17
  • CapEx intensity
  • Current Ratio
  • Price below Graham Number
  • DCF valuation (Overvalued)
  • Revenue Growth 5Y 0.3%
  • Earnings Surprise avg 2.4%
  • Earnings Quality (OCF/NI) 0.66
  • Piotroski F-Score 1/9

Nicht verfügbar (6)

  • EPS data insufficient
  • Dividend Payout NaN%
  • Interest Coverage
  • Return on Tangible Assets
  • Low reliance on intangibles
  • Share Dilution (missing shares data)

Piotroski F-Score

1/9

Ernsthafte finanzielle Bedenken

score
criteria

Gewinnqualität

0.66

Mittel: Gewisse Differenz zwischen Gewinn und Cashflow

Aktienverwässerung

-

Aktienrückkäufe. Aktionärsfreundlich

Unternehmensführung

Führungsteam

NamePositionAlter
Mr. Kristoffer Loe LichtCEO & Executive Director49
Ms. Shannon Sue EisenhardtCFO & Executive Director51
Mr. Nicholas James Ashworth C.F.A.Senior Vice President of Investor Relations-
Ms. Catheryn O'RourkeSenior VP, General Counsel & Company Secretary52
Ms. Sheila RedzepiChief Communications & Corporate Affairs Officer46
Mr. Ranjay RadhakrishnanChief Human Resources Officer54
Mr. Jerome LemairePresident North America51
Ms. Angela Naef Ph.D.Chief Research & Development Officer49
Ms. Susan SholtisPresident of Nutrition58
Dr. Alessio Fasano M.D.Chief Science & Medical Officer of Mead Johnson Nutrition (MJN) Business-

Prüfungsrisiko

4

Vorstandsrisiko

2

Vergütungsrisiko

3

Aktionärsrechterisiko

1

Teil 2 · Der Preis und der Einstiegszeitpunkt

Dieser Teil sagt nicht, ob das Unternehmen etwas taugt: Er hilft bei der Wahl des Kaufzeitpunkts, nachdem die Fundamentaldaten überzeugt haben. Enthalten: technische Analyse, Potenzial, historische Drawdowns, Gamma-Exposure.

Latest News

Recent headlines for RBGPF, sourced from Markets Gazette.

No recent news for RBGPF.